Table 2.
Neoadjuvant, adjuvant, and total chemotherapy cycles, by total-time-to-surgery (TTS)a, in 2,267 patients with locally advanced rectal cancer, January 2010 through December 2018.
| TTSa group | Total patients | Neoadjuvant chemotherapy | Adjuvant chemotherapy | Total chemotherapy | |||
|---|---|---|---|---|---|---|---|
| No. of patients (%) | No. of cycles mean, SD | No. of patients (%) | No. of cycles mean, SD | No. of patients (%) | No. of cycles mean, SD | ||
| TTS-1 (<13 weeks) | 657 | 653 (99.4) | 2.5 ± 0.8 | 537 (81.7) | 4.0 ± 2.6 | 654 (99.5) | 6.5 ± 2.8 |
| TTS-2 (13 to <15 weeks) | 616 | 613 (99.5) | 3.2 ± 1.3 | 515 (83.6) | 4.0 ± 2.5 | 615 (99.8) | 7.1 ± 3.1 |
| TTS-3 (15 to <17 weeks) | 465 | 454 (97.6) | 3.7 ± 1.5 | 370 (79.6) | 3.2 ± 2.4 | 465 (100.0) | 7.0 ± 2.9 |
| TTS-4 (≥17 weeks) | 529 | 528 (99.8) | 4.6 ± 2.2 | 384 (72.6) | 2.7 ± 2.2 | 528 (99.8) | 7.3 ± 2.9 |
a
Total-time-to-surgery (TTS) defined as time from initiation of neoadjuvant treatment to date of surgery.